Vesting of long term options tied to the milestone of selling the drug.
Did I read wrong that they had $85 million cash?
That means they probably now have about $150-160 million, right?
It should not be substantially different from the amount of training required to already do dialysis and IV iron. This stuff is done by trained professionals and they should be able to adapt.
They have only been wrong if they sold at a loss. The smartest money in the room and Baupost accumulated and do on weakness. I want to own this stock now for the 2016-2024 cashflow.
Why would they take triferic if they don't need to take IV iron. It is an IV iron alternative. Removing the need for IV iron is analogous to removing the need for triferic. This is an enormous benefit to patients. For those that will have to still supplement their iron during dialysis, triferic is probably going to take market share, but there is no doubt auryxia will slow the growth of that market (slow the growth, not kill the market). Both drugs will probably find success. I would be wary of shorting any next generation nephrology medications.
I am guessing that is a monthly supply.
5,400x800x12=51,840,000 That is the annual revenue from 5,400 patients.
If they got that per month for one year, then at the end of one year, they would have 64,800 patients, that would produce revenue of about $620 million the following year, based on that bottle price.
Not much because they are negotiating with entities and would be wise to say little that might become material in ongoing discussions. It will be vaguely positive though.
The dividend is going ex, and it is the last 75 cent div, voted for at last year's annual meeting. Swiss companies cannot change their dividends willy nilly. It is a shareholder matter...they can only suggest a yearly policy for voters to set by voting.
Do you see that orderly and almost smooth line down, clearly to many lots and also triggering some stops around 17, then 16.75 and then 16.50. It looks like some HFT bots ganged up on another bot or fund that was selling out of a position yesterday.
are you sure that auryxia increases AL, because I am pretty sure it does not significantly affect levels, if at all, and the drug is not considered an aluminum-type phosphate binder. Do you have a source for these level readings?
How is it average? It is as effective at phosphate binding plus increases iron absorption. You choose to ignore what is clearly an important part of the drug's profile and then expect to be taken seriously, but that is not how things work.
So the clinical results indicate the increase was not significant and they have already stated is is not significant, but you want him to ask whether it is an issue.
The appreciation since your purchase is already better than the dividend anyway, and you will get lots of dividends over the years.
The dividend is an aristocrat, and the only reason it does not appear so healthy is because of share appreciation, which is also quite nice.